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Nonalcoholic fatty liver disease (NAFLD) is a wide-spectrum 
disease entity from simple hepatic steatosis to nonalcoholic 
steatohepatitis (NASH) and cirrhosis. After Ludwig et al
1 
introduced the name of NASH firstly in 1980, the concerns 
about NASH have been explored intensively. The majority of 
cryptogenic cirrhosis diagnosed in the past presume the 
progressed state of NASH. Approximately 90% of abnormal 
liver function without specific causes such as virus, alcohol, 
toxic and genetic factor presumes NAFLD.
2 For diagnosis of 
NAFLD, several causes which can induce hepatic steatosis 
should be excluded such as protein-calorie malnutrition, starvation, 
total parenteral nutrition, rapid weight loss, amiodarone, 
methotraxate, valproic acid, glucocorticoid, calcium-channel 
blocker, tamoxifen, tetracycline, and aspirin.
2 Although the 
prevalence of NAFLD is different among countries and races, 
about 10-20% of general population may have NAFLD.
2
Simple hepatic steatosis is usually thought as a non-progressive 
condition,
3 but about 5% of hepatic steatosis can progress to 
NASH.
4 In contrast to hepatic steatosis, approximately 30% of 
NASH shows the progression of fibrosis within 5 years;
5 about 
20% of NASH progresses to cirrhosis during lifetime.
6 Once 
cirrhosis is developed, the risk of complications of cirrhosis is 
increased such as ascites, variceal bleeding, hepatic encephalopathy 
and development of hepatocellular carcinoma.
7 NASH should be 
discriminated from simple hepatic steatosis because of the above 
reasons. Liver biopsy is still gold standard for differentiating 
between steatosis and NASH. The pathologic findings of NASH 
are macrovesicular steatosis, lobular inflammation, Mallory 
bodies, ballooning degeneration, and perisinusoidal/perivenular 
fibrosis. Using these parameters, Brunt et al
8 introduced necro-
inflammatory grade and fibrosis score system for NASH in 1999. 
Recently, NASH Clinical Research Network introduced new 
system in which the degrees of steatosis, lobular inflammation, 
hepatocyte ballooning and Mallory bodies are scored as NAFLD 
activity score (NAS).
9 NASH can be differentiated from hepatic 
steatosis with NAS system. However, liver biopsy is an invasive 
procedure with significant complication like bleeding. Several 
non-invasive biomarkers for diagnosis of NASH have been 
investigated recently. Palekar et al
10 investigated the model for 
predicting NASH using 8-epi-PGF2α, TGF-β, hyaluronic acid 
and adiponectin (sensitivity: 73.7%, specificity: 65.7%, positive 
predictive value: 68.2%, negative predictive value: 68.2%). 
Poynard et al
11 introduced the model, Steatotest for predicting 
over 30% steatosis using alanine aminotransferase (ALT), 
a2-macroglobulin, apolipoprotein A-I, haptoglobin, total bilirubin, 
γ-glutamyl transpeptidase (GGT), cholesterol, triglycerides, 
glucose, age, gender and body mass index (BMI) (sensitivity: 
90%, specificity: 90%, negative predictive value: 93%, positive 
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advanced fibrosis (F3, F4) using α2-macroglobulin, apolipoprotein 
A-I, haptoglobin, total bilirubin, GGT and ALT (positive 
predictive value: 73%, negative predictive value: 90%).
12 
Similarly, NAFLD fibrosis score was investigated for 
predicting advanced fibrosis using age, hyperglycemia, BMI, 
platelet count, albumin and aspartate aminotransferase (AST)/ 
ALT ratio (positive predictive value: 82%, negative predictive 
value: 93%).
13 Several inflammatory mediators are increased in 
NASH compared to simple hepatic steatosis such as tumor 
necrosis factor (TNF)-α, interleukin-6 (IL-6), CC-chemokine 
ligand 2 (CCL-2), and hyaluronic acid.
14-16
Deregulation of hepatocyte apoptosis is an important mechanism 
of liver injury and NASH development.
17-19 Fas has a critical role 
in apoptosis pathway as a death receptor member of the TNF 
receptor family. Expression of this membrane protein is 
increased in NASH patients.
17 Accumulation of free fatty acids 
in hepatocytes results in up-regulation of Fas in the cell 
membrane which increases the sensitivity to Fas mediated 
apoptosis.
20 At the level of mitochondria, apoptosis pathway 
induces permiabilization of the mitochondrial outer membrane 
and release of multiple protein from the mitochondrial inner 
membrane space to cytoplasm.
21 This results in activation of 
effector caspases (mainly caspase 3) which will cleave substrates 
in cytoplasm like cytokeratin 18 (CK-18), the major intermediate 
filament protein of liver, inducing the specific morphologic 
change of apoptosis.
21 There are several reports showing that the 
quantification of this caspase generated CK-18 fragments is 
useful for diagnosis of NASH.
22-25
In subject study, they investigated the apoptosis panel for 
non-invasive diagnosis of NASH using these two biomarkers, 
serum CK-18 fragments and soluble Fas (sFas). Compared to 
each single biomarker, the combination of two biomarkers, 
serum CK-18 fragments and sFas showed significantly higher 
area under curve (AUC) (0.86 in CK-18, 0.86 in sFas and 0.93 in 
CK-18 with sFas), sensitivity (88%), and specificity (89%) for 
diagnosis of NASH. The high AUC in the validation group (0.79) 
indicates the reproducibility of this apoptosis panel. This 
apoptosis panel for NASH diagnosis is non-invasive, simple, 
reproducible and reliable method which is needed in real clinical 
situation. Not only for diagnosis but also for assessment of 
treatment response and prognosis, this apoptosis panel with 
serum CK-18 fragments and sFas could be used after proper 
researches are done.
In conclusion, this diagnostic apoptosis panel including serum 
CK-18 fragments and sFas for diagnosis of NASH is useful test 
in clinical practice for noninvasive diagnosis of NASH as a 
simple, easy to measure, reproducible and reliable method. 
Further studies are needed to validate the accuracy of this 
apoptosis panel for NASH diagnosis in each race and country. 
We need to investigate whether this apoptosis panel could be 
used for assessment of treatment response and predicting 
prognosis of NASH.
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